Synairgen plc Result of AGM (4493J)
28 June 2017 - 9:41PM
UK Regulatory
TIDMSNG
RNS Number : 4493J
Synairgen plc
28 June 2017
Press release
Synairgen plc
('Synairgen' or the 'Company')
Result of Annual General Meeting
Southampton, UK - 28 June 2017: Synairgen (LSE: SNG), the
respiratory drug discovery and development company, is pleased to
announce that all resolutions proposed at its Annual General
Meeting, held earlier today, were duly passed.
- Ends -
For further enquiries, please contact:
Synairgen plc
Richard Marsden, Chief Executive Officer
John Ward, Finance Director
Tel: + 44 (0) 23 8051 2800
finnCap
Geoff Nash, James Thompson (Corporate Finance)
Stephen Norcross, Simon Johnson (Corporate Broking)
Tel: + 44 (0) 20 7220 0500
Consilium Strategic Communications (Financial Media and
Investor
Relations)
Mary-Jane Elliott / Sue Stuart / Jessica Hodgson / Laura
Thornton
synairgen@consilium-comms.com
Tel: +44 (0) 20 3709 5701
Notes for Editors
About Synairgen
Synairgen is a respiratory drug discovery and development
company founded by University of Southampton Professors Stephen
Holgate, Donna Davies and Ratko Djukanovic. The business, focused
primarily on asthma and COPD, uses its differentiating human
biology BioBank platform and world-renowned international academic
KOL network to discover and develop novel therapies for respiratory
disease. Leveraging its scientific and clinical facilities at
Southampton General Hospital, the Company uses in vitro and ex vivo
models to progress opportunities into clinical development. The
BioBank of human samples is used in these models to increase
confidence in the likelihood of successful drug development. Core
to Synairgen's business strategy is the realisation of value via
licensing transactions. In August 2015 the Company entered into a
collaboration with Pharmaxis to develop an oral LOXL2 inhibitor to
reduce fibrosis in patients with idiopathic pulmonary fibrosis
(IPF). Synairgen is quoted on AIM (LSE: SNG). For more information
about Synairgen, please see www.synairgen.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
RAGBBGDLLXDBGRI
(END) Dow Jones Newswires
June 28, 2017 07:41 ET (11:41 GMT)
Synairgen (LSE:SNG)
Historical Stock Chart
From Apr 2024 to May 2024
Synairgen (LSE:SNG)
Historical Stock Chart
From May 2023 to May 2024
